- Previous Close
2.9400 - Open
2.9500 - Bid 2.9600 x 200
- Ask 3.0200 x 100
- Day's Range
2.9100 - 3.0200 - 52 Week Range
2.2150 - 6.4400 - Volume
301,270 - Avg. Volume
764,706 - Market Cap (intraday)
666.213M - Beta (5Y Monthly) 2.62
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4000 - Earnings Date Nov 12, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.00
CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
www.curevac.comRecent News: CVAC
View More
Performance Overview: CVAC
Trailing total returns as of 10/1/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CVAC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CVAC
View MoreValuation Measures
Market Cap
667.33M
Enterprise Value
480.56M
Trailing P/E
--
Forward P/E
5.24
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.06
Price/Book (mrq)
1.59
Enterprise Value/Revenue
6.53
Enterprise Value/EBITDA
-0.66
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.52%
Return on Equity (ttm)
-54.30%
Revenue (ttm)
65.86M
Net Income Avi to Common (ttm)
-278.43M
Diluted EPS (ttm)
-1.4000
Balance Sheet and Cash Flow
Total Cash (mrq)
202.52M
Total Debt/Equity (mrq)
10.37%
Levered Free Cash Flow (ttm)
-222.1M
Research Analysis: CVAC
View MoreCompany Insights: CVAC
CVAC does not have Company Insights
Research Reports: CVAC
View MoreCureVac Earnings: Early-Stage Pipeline Makes Progress; GSK Agreement and Reorganization Extend Cash
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
RatingPrice TargetCureVac: New Agreement With GSK Provides Capital Boost; Leaner Operations Should Extend Cash Runway
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company’s other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
RatingPrice TargetCureVac Earnings: Reorganization Aims to Extend Cash Runway; Intellectual Property Battle Ongoing
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GSK to develop a second-generation covid vaccine. CureVac’s first attempt to develop a covid vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company’s other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
RatingPrice TargetCureVac Earnings: Reorganization Aims to Extend Cash Runway; Intellectual Property Battle Ongoing
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GSK to develop a second-generation covid vaccine. CureVac’s first attempt to develop a covid vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company’s other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
RatingPrice Target